PreludeDx™ Presents New Data at SABCS Spotlight Session Re-Classifying Patients Meeting RTOG 9804 Low Risk Criteria as Elevated Risk Using DCISionRT®
Share this article Share this article LAGUNA HILLS, Calif., Dec. 15, 2020 /PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented clinical outcomes data last week at the San Antonio Breast Cancer Symposium (SABCS) that further validates the DCISionRT® test results of an independent study by Kaiser Permanente Northwest published earlier this year in Clinical Cancer Research. DCISionRT is a biologic risk signature that assess the 10-yr risk of a subsequent breast cancer recurrence. A Spotlight Po...
Source: prnewswire.com